FLT3 TKD MUTATION

CI-VAR-00004357Explore in graph →CIViC 56

Curated evidence

Evidence by cancer (8 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–8 of 8 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Acute Lymphoblastic Leukemia1
FLT3 ITD OR FLT3 TKD MUTATION OR NRAS EXON 2-3 MUTATION OR PTPN11 Mutation OR KRAS Exon 2-3 Mutation	Selumetinib	Predictive	D	Supports Sensitivity Response	2	submitted	EID12553 In a preclinical genomic and functional study of pediatric acute lymphoblastic leukemia (n = 81 paired diagnosis–relapse samples), recurrent RAS-pathway mutations involving NRAS (exons 2-3), KRAS (exo… (full text at CIViC) PMID 24316979 · Wong et al., 2014 · Open in CIViC	civic
Acute Myeloid Leukemia7
FLT3 TKD MUTATION	(prognostic)	Prognostic	B	Supports Better Outcome	3	accepted	EID171 Event-free survival was significantly improved in patients with both NPM1 and FLT3-TKD mutations compared to patients with 1) FLT3-TKD mutations alone 2) either NPM1 or FLT3-TKD when FLT3-ITD patients…

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.